Live
FierceBiotechLilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience playFierceBiotechBMS links up with Faro to use AI to improve clinical trial protocolsFierceBiotechObesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinicFierceBiotechStill reeling from FDA refusal, IO Biotech surrenders to bankruptcyEndpoints NewsColorado biotech Ambrosia lands $100M for oral GLP-1Endpoints NewsAstellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forwardLonza NewsLonza links up with Torqur on bimiralisib manufacturing - The Pharma LetterBioPharma DiveViridian tumbles on positive data for key eye drug prospect10x Genomics Blog10x Genomics (NASDAQ:TXG) Shares Gap Up Following Analyst Upgrade - MarketBeatPromega BlogDown the Rabbit Hole: The Search for New England’s Disappearing CottontailAgilentIs New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies (A)? - simplywall.stEndpoints NewsAvo raises $10M to help clinicians with workflow
FierceBiotech Mar 31, 2026

Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy

Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy

Original
Body unavailable. Use the original source.

Directory

59 All